Pradaxa reversal drug, Praxbind, receives FDA nod for emergency situations

The U.S. Food and Drug Administration Friday granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa's blood-thinning effects. "The anticoagulant effects of Pradaxa are important and life-saving for some patients, but there are situations where reversal of ["]